Katz M E, Schwartz P E, Kapp D S, Luikart S
Ann Intern Med. 1981 Jul;95(1):98-111. doi: 10.7326/0003-4819-95-1-98.
Epithelial ovarian cancer is usually diagnosed late in its biologic course (70% of cases are diagnosed as stage III or IV). Recent advances in chemotherapy and radiation therapy offer the possibility of long-term disease-free survival and the potential for cure. The selection of treatment for disease confined to the pelvis (stage I or II) remains controversial. After total abdominal hysterectomy, bilateral salpingo-oophorectomy, and omentectomy, high risk patients probably should receive abdominopelvic irradiation or chemotherapy; the relative roles of these two modalities are currently under study. Stage III consists of cases of minimal residual disease at surgery, minimal residual disease after debulking surgery, and residual large bulky tumor masses. Patients with minimal residual disease are best treated with either abdominopelvic radiation or chemotherapy; patients with stage IV or bulky stage III disease, with chemotherapy. Despite the multiplicity of active single agents, only one study to date has shown a statistically significant improvement in survival for patients with advanced disease utilizing combination chemotherapy.
上皮性卵巢癌通常在其生物学进程的晚期才被诊断出来(70%的病例被诊断为III期或IV期)。化疗和放射治疗的最新进展为长期无病生存以及治愈提供了可能性。对于局限于盆腔的疾病(I期或II期),治疗方案的选择仍存在争议。在全腹子宫切除术、双侧输卵管卵巢切除术和大网膜切除术后,高危患者可能应接受腹盆腔放疗或化疗;目前正在研究这两种治疗方式的相对作用。III期包括手术时残留病灶最小、肿瘤细胞减灭术后残留病灶最小以及残留大块肿瘤肿物的病例。残留病灶最小的患者最好接受腹盆腔放疗或化疗;IV期或大块III期疾病的患者则接受化疗。尽管有多种有效的单一药物,但迄今为止只有一项研究表明,使用联合化疗的晚期疾病患者的生存率有统计学上的显著提高。